- Home
- MCRB vs ACHV Comparison
MCRB vs ACHV Comparison
Compare MCRB & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ACHV
- Stock Information
- Founded
- MCRB 2010
- ACHV N/A
- Country
- MCRB United States
- ACHV United States
- Employees
- MCRB N/A
- ACHV N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MCRB Health Care
- ACHV Health Care
- Exchange
- MCRB Nasdaq
- ACHV Nasdaq
- Market Cap
- MCRB 125.7M
- ACHV 131.3M
- IPO Year
- MCRB 2015
- ACHV N/A
- Fundamental
- Price
- MCRB $19.44
- ACHV $2.92
- Analyst Decision
- MCRB Hold
- ACHV Strong Buy
- Analyst Count
- MCRB 4
- ACHV 2
- Target Price
- MCRB $73.67
- ACHV $16.00
- AVG Volume (30 Days)
- MCRB 126.4K
- ACHV 748.4K
- Earning Date
- MCRB 08-06-2025
- ACHV 08-07-2025
- Dividend Yield
- MCRB N/A
- ACHV N/A
- EPS Growth
- MCRB N/A
- ACHV N/A
- EPS
- MCRB 10.22
- ACHV N/A
- Revenue
- MCRB N/A
- ACHV N/A
- Revenue This Year
- MCRB N/A
- ACHV N/A
- Revenue Next Year
- MCRB N/A
- ACHV N/A
- P/E Ratio
- MCRB $1.98
- ACHV N/A
- Revenue Growth
- MCRB N/A
- ACHV N/A
- 52 Week Low
- MCRB $6.53
- ACHV $1.84
- 52 Week High
- MCRB $26.40
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- MCRB 69.44
- ACHV 62.28
- Support Level
- MCRB $15.79
- ACHV $2.55
- Resistance Level
- MCRB $18.12
- ACHV $3.10
- Average True Range (ATR)
- MCRB 1.51
- ACHV 0.16
- MACD
- MCRB 0.28
- ACHV 0.05
- Stochastic Oscillator
- MCRB 97.69
- ACHV 75.34
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.